US pharma giant Eli Lilly's Mounjaro can prove crucial in treatment of obesity & type 2 diabetes. Launched in the US in 2022, ...

Compounding pharmacies have been allowed to essentially make a cheaper version of Eli Lilly's Zepbound, but they have to stop ...

Addiction and obesity share deep neurological roots. Can new treatments like GLP-1 drugs and MEAI help break the cycle?

The versions affected are called compounded medications, which have the same active ingredients as the name brands. The ...

Large-scale compounding facilities have to stop making tirzepatide, the main ingredient in blockbuster obesity drug Zepbound, Wednesday.

A new study found that fair prices for medications like Wegovy and Zepbound would be hundreds less per month than they are ...

and effective medicine. LillyDirect is Eli Lilly and Company’s direct-to-consumer digital healthcare platform. Eligible Teladoc Health members, if prescribed Zepbound by their Teladoc Health ...

Under the agreement, eligible Teladoc Health members prescribed Zepbound by their provider ... clinicians with specialized training in obesity medicine, registered dietitians, and health coaches.

To use the vials, people have to draw out the medicine with a syringe and inject themselves with a needle. Before launching the Zepbound vials in 2024, Eli Lilly offered the drug only in a single ...

Zepbound brought in almost $5 billion in revenue ... So to say, well there is this medicine available but you have to pay for it out of pocket, it really serves a small percentage of the population." ...